Additionally, responders demonstrated a potent immune response at the tumor site, characterized with higher frequencies of IFNγ+CD8 T cells, upregulation of genes in pathways relating to innate and adaptive immune activation, and diversification of intratumoral T-cell repertoire that was dominated by specific T-cell clones [30]. The gene discussed is CD8A; the disease is neoplasm.